Clinical Trial

Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta

Recruiting
View on ClinicalTrials.gov →
Summary
Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1/3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative/postoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0/7-37 6/7 weeks of gestation with those at 36 0/7-36 6/7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-07-11
Trial Details
NCT Number NCT07025954
Lead Sponsor The Third Affiliated Hospital of Guangzhou Medical University
Conditions Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section, Preterm Birth Complication
Enrollment 600 participants
Start Date 2025-07-12
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-16